Jin and colleagues conducted a multicenter study that examined the efficacy and safety of telitacicept in everyday clinical practice and they found favorable outcomes in patients with active SLE, with significant decreases in serum IgA, IgG, and IgM levels and improvements in renal and hematological manifestations of the disease. The gene discussed is CD79A; the disease is systemic lupus erythematosus.